Navigation Links
Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
Date:9/25/2013

HAYWARD, Calif., Sept. 25, 2013 /PRNewswire/ -- Anthera Pharmaceuticals (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that emerging data from its Phase 2b PEARL-SC study and subsequent Open-Label Extension study will be presented by Dr. Richard Furie at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP).

Two abstracts, an oral presentation and a poster, will summarize interim findings from analyses of the Open-Label Extension study pertaining to the durability of effects of blisibimod over 52 weeks on renal biomarkers, including proteinuria and Complement C3, and serum immunoglobulins, including IgG and IgM.

The immunoglobulins IgG and IgA are thought to play a significant role in IgA nephropathy (IgAN). According to the Journal of Clinical Investigation, IgAN is characterized by immune complexes composed of galactose-deficient IgA1 (immunogenic IgA) and a glycan-specific IgG antibody that deposit in the kidneys.

"IgG and immunogenic IgA, when combined, form a complex that deposits in the kidney leading to a slow, insidious loss of kidney function," said Dr. Jonathan Barratt, an IgA nephropathy specialist from the University of Leicester. "Any data that demonstrate a decrease in serum immunoglobulin levels provide further evidence for blisibimod's potential effectiveness in treating patients with IgA nephropathy."

"We're very excited to be able to present data which provides additional insight into the role of blisibimod administration on immunoglobulin levels in patients with autoimmune diseases. They are a key component of what we discussed with the FDA and are exploring in the BRIGHT-S
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
2. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
3. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
4. Anthera Pharmaceuticals Announces Personnel Changes
5. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
6. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
7. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
8. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
9. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
11. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... , NEW YORK, Dec. 2 ... available in its catalogue: , Pharmaceutical Contract ... http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html , Global pharma industry ... in generic markets, rising cost of new product development, ...
... , JUPITER, Fla., Dec. 2 Jupiter Medical ... diagnostic tools available into its imaging program, the new Signa ... highly detailed images of the human body with increased speed, ... non-contrast vascular imaging for patients with renal dysfunction. This ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5Jupiter Medical Center Announces New High-Definition MRI System 2
(Date:7/12/2014)... United Arab Emirates (PRWEB) July 12, 2014 ... another Los Angeles basketball legend is heading to the ... scorer and six-time champion will be in the UAE ... & Fitness Weekend in support of diabetes awareness. The ... an award-winning entertainment marketing and event management company based ...
(Date:7/12/2014)... Los Angeles, CA (PRWEB) July 12, 2014 ... a buyer power score of 4.1 out of ... the market that have been underpinning buyer negotiation ... to IBISWorld procurement analyst Anna Son, “during the ... along with rising costs associated with new product ...
(Date:7/11/2014)... (PRWEB) July 12, 2014 Recently, DressyQuinceanera.com, ... 200 Quinceanera Dama dresses to its online ... items are offered at deeply discounted rates, up to ... from DressyQuinceanera.com are equally excellent in terms of quality ... carefully handmade. Similar discounts are also offered for the ...
(Date:7/11/2014)... Lewisberry, PA (PRWEB) July 11, 2014 Butler ... line of Inclined Platform Lifts . Previously the ... now offering five new beautiful earth tone colors as standard ... only blend well in the home but will enhance the ... color choice for any home color scheme or individual décor. ...
(Date:7/11/2014)... July 11, 2014 Microbiology testing is ... in-vitro diagnostics industry, which is expected to pose the ... The sector owes its growth to the ongoing spread ... health worldwide and a major factor leading to the ... of bio-terrorism, and a broader availability of immunosuppressants, among ...
Breaking Medicine News(10 mins):Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3
... 113 children and teens physically victimized by peers concludes ... and diffuse threats makes them far less likely to ... immediate aftermath of the attack. , The research, by ... Medical Center in Washington, D.C., was conducted on 10- ...
... The International Diabetes,Federation (IDF) announced today that Ms ... Officer/Executive Director., The International Diabetes Federation, headquartered ... 200 diabetes associations,worldwide. It is the global advocate ... their families, and healthcare providers., Ms Keeling ...
... home safety review could cut odds of fractures in those ... Former first lady Nancy Reagan and Democratic presidential candidate ... And on Friday, author Studs Terkel died, following reports that ... Such news, experts say, should be a reminder to all ...
... study shows that an imaging technology developed by Mayo ... and help eliminate the need for liver biopsies. ... to incurable cirrhosis if not treated in time. , ... images known as elastograms that indicate how internal organs, ...
... health care coverage, yet oppose a government mandate to do so, a ... candidates’ health care proposals. , ... New York, NY (PRWEB) November 1, ... health care coverage, yet oppose a government mandate to do ...
... study in the Nov. 1 issue of the journal ... specific neurochemical abnormality in adults with primary insomnia, providing ... pathology. , Results indicate that gamma-aminobutyric acid (GABA), ... reduced by nearly 30 percent in individuals who have ...
Cached Medicine News:Health News:Memo to ER docs: Send young victims of violence for 1-on-1 counseling 2Health News:Memo to ER docs: Send young victims of violence for 1-on-1 counseling 3Health News:New Chief Executive Officer Joins International Diabetes Federation 2Health News:Falls Are Leading Cause of Injury to Seniors 2Health News:Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease 2Health News:Employers “Vote” on Presidential Candidates' Health Care Platforms: Prefer Middle Ground Between the Two Approaches 2Health News:Employers “Vote” on Presidential Candidates' Health Care Platforms: Prefer Middle Ground Between the Two Approaches 3Health News:Study links primary insomnia to a neurochemical abnormality in young and middle-aged adults 2Health News:Study links primary insomnia to a neurochemical abnormality in young and middle-aged adults 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: